comparison. Local price lists were used to estimate the cost for drug, administration and withdrawals. Two cost-effectiveness scenarios were conducted; one clinical trial scenario, (52 weeks use of Ferric maltol), and one clinical practice scenario, where the use of Ferric maltol was more in line with the expected use in clinical practice (12 weeks). Time horizon was one year (no discount rate). Stochastic and one-way sensitivity analyses were conducted. RESULTS: In the clinical trial scenario ferric maltol saved costs (Sweden: Euro 188.5; Finland: Euro 633) at the expense of slight losses in QALYs (0.002) and response weeks (0.9). The cost saving per lost QALY was Euro 113,751 (Sweden) and 381,750 (Finland). In the clinical practice scenario, the cost savings (Sweden: Euro 528.8; Finland: Euro 1,068) and losses in QALYs (0.008) and response weeks (4.1) were larger. The cost saving per lost QALY was Euro 69, 615 (Sweden) and 140,588 (Finland). CONCLUSIONS: Ferric maltol was cost saving in Sweden and Finland compared to ferric carboxymaltose at minimal loss in QALYs. Hence ferric maltol can be considered as good use of money in the treatment of iron deficiency anaemia in IBD patients in Sweden and Finland.
We present a clinical case of a 39-year-old man, with no significant chronic degenerative or hereditary history, who begins with a clinical course of gastrointestinal bleeding with hematological repercussions, with cabinet studies (panendoscopy-colonoscopy) without evidence of hemorrhage site so it was performed enterotomography with report of increased volume and density of the mesentery of ileum segment, hyperdense and irregular linear images that increase density without enhancement with «halo» sign, concentric thickening of segment 25cm ileum, with diminished light and mucosa sfaccelada to 40 cm proximal to the ileocecal valve, coarse calcifications in mesentery. Exploratory laparotomy was performed with resection of distal ileum plus right hemicolectomy plus entire side-to-side anastomosis. With histopathological report of mesenteric lymphangiomatosis. Mesenteric lymphangiomatosis is a rare entity with a good prognosis if complete surgical resection is performed. RESUMENPresentamos un caso clínico de un hombre de 39 años, sin antecedentes crónico-degenerativos ni heredofamiliares de importancia, que inicia con cuadro clínico de hemorragia de tubo digestivo con repercusión hematológica, con estudios de gabinete (panendoscopiacolonoscopia) sin evidenciarse sitio de hemorragia, por lo que se le realizó enterotomografía con reporte de aumento de volumen y densidad del mesenterio de segmento de íleon, imágenes lineales hiperdensas e irregulares que aumentan la densidad sin realce con signo del «halo», engrosamiento concéntrico de segmento 25 cm de íleon, con disminución de la luz y mucosa esfacelada a 40 cm proximal a la válvula ileocecal, calcificaciones gruesas en mesenterio. Realizándose laparotomía exploradora con resección de íleon distal más hemicolectomía derecha más entero-entero-anastomosis-laterolateral. Con reporte histopatológico de linfangiomatosis mesentérica. La linfangiomatosis mesentérica es una entidad poco común con un pronóstico bueno si se realiza resección quirúrgica completa.Palabras clave: Hemorragia digestiva, linfangiomatosis mesentérica.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.